Clinical trial
Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced…
NCT00203164 · Teva Branded Pharmaceutical Products R&D, Inc., Industry · Completed
Key facts
| NCT number | NCT00203164 |
|---|---|
| Title | Study to Evaluate the Safety and Tolerability of Rasagiline in Advanced Parkinson's Disease Patients |
| Official title | A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy |
| Lead sponsor | Teva Branded Pharmaceutical Products R&D, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | rasagiline mesylate |
| Enrollment | 254 |
| Start date | May 1, 2002 |
| Primary completion | Jul 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 9, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: